GlaxoSmithKline PLC (NYSE:GSK) Shares Sold by Capital Asset Advisory Services LLC

Capital Asset Advisory Services LLC decreased its stake in GlaxoSmithKline PLC (NYSE:GSK) by 1.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,998 shares of the pharmaceutical company’s stock after selling 218 shares during the period. Capital Asset Advisory Services LLC’s holdings in GlaxoSmithKline PLC were worth $519,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in GSK. 10 15 Associates Inc. increased its position in shares of GlaxoSmithKline PLC by 6.4% in the first quarter. 10 15 Associates Inc. now owns 237,716 shares of the pharmaceutical company’s stock worth $10,022,000 after buying an additional 14,247 shares in the last quarter. Lincluden Management Ltd. increased its position in shares of GlaxoSmithKline PLC by 1.7% in the first quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock worth $5,095,000 after buying an additional 1,990 shares in the last quarter. Anchor Capital Advisors LLC increased its position in shares of GlaxoSmithKline PLC by 9.6% in the first quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock worth $25,858,000 after buying an additional 53,894 shares in the last quarter. BlueCrest Capital Management Ltd increased its position in shares of GlaxoSmithKline PLC by 293.5% in the first quarter. BlueCrest Capital Management Ltd now owns 51,157 shares of the pharmaceutical company’s stock worth $2,157,000 after buying an additional 38,157 shares in the last quarter. Finally, Roundview Capital LLC increased its position in shares of GlaxoSmithKline PLC by 157.4% in the first quarter. Roundview Capital LLC now owns 24,529 shares of the pharmaceutical company’s stock worth $1,034,000 after buying an additional 15,000 shares in the last quarter. Hedge funds and other institutional investors own 8.96% of the company’s stock.

GlaxoSmithKline PLC (NYSE:GSK) traded down 0.28% on Friday, reaching $38.79. The company had a trading volume of 2,324,396 shares. The company has a market capitalization of $94.80 billion, a PE ratio of 37.51 and a beta of 1.03. GlaxoSmithKline PLC has a 52-week low of $37.20 and a 52-week high of $44.59. The company’s 50-day moving average is $41.99 and its 200-day moving average is $41.84.

GlaxoSmithKline PLC (NYSE:GSK) last posted its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. Equities analysts anticipate that GlaxoSmithKline PLC will post $2.85 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be given a $0.491 dividend. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 annualized dividend and a dividend yield of 5.06%. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is currently 197.00%.

WARNING: This news story was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://www.com-unik.info/2017/08/11/glaxosmithkline-plc-nysegsk-stake-reduced-by-capital-asset-advisory-services-llc-updated-updated-updated.html.

A number of equities research analysts have recently weighed in on GSK shares. TheStreet upgraded GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research report on Friday, May 19th. Berenberg Bank upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th. Zacks Investment Research upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating and set a $47.00 price objective on the stock in a research report on Tuesday, July 18th. ValuEngine lowered GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Monday, July 24th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $46.00.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

What are top analysts saying about GlaxoSmithKline PLC? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline PLC and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit